These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 345572)

  • 21. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

  • 24. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees.
    Mukerjee CM; McKenzie DK
    Aust N Z J Med; 1985 Apr; 15(2):226-9. PubMed ID: 3861165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Isoniazid-induced hepatic failure. Report of a case].
    Pereira RM; Tresoldi AT; Hessel G
    Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.
    Tubercle; 1982 Jun; 63(2):89-98. PubMed ID: 6758252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
    Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
    Schaberg T; Rebhan K; Lode H
    Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
    Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
    Türktaş H; Unsal M; Tülek N; Orüç O
    Tuber Lung Dis; 1994 Feb; 75(1):58-60. PubMed ID: 8161767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
    Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
    Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
    Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
    Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic complications of antituberculosis therapy revisited.
    Cohen CD; Sayed AR; Kirsch RE
    S Afr Med J; 1983 Jun; 63(25):960-3. PubMed ID: 6857425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled clinical trial of three short-course regimens of chemotherapy for pulmonary tuberculosis in Nigeria--a preliminary report.
    Onadeko BO; Awotedu AA; Ogunbanjo BO; Aderinto EB
    Tubercle; 1986 Sep; 67(3):189-95. PubMed ID: 3535187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.